High-grade glioma formation results from postnatal Pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model

Qingxia Wei, Laura Clarke, Danielle K. Scheidenhelm, Baoping Qian, Amanda Tong, Nesrin Sabha, Zia Karim, Nicholas A. Bock, Robert Reti, Rolf Swoboda, Enkhtsetseg Purev, Jean Francois Lavoie, M. Livia Bajenaru, Patrick Shannon, Dorothee Herlyn, David Kaplan, R. Mark Henkelman, David H. Gutmann, Abhijit Guha

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

High-grade gliomas are devastating brain tumors associated with a mean survival of <50 weeks. Two of the most common genetic changes observed in these tumors are overexpression/mutation of the epidermal growth factor receptor (EGFR) vIII and loss of PTEN/MMAC1 expression. To determine whether somatically acquired EGFRvIII expression or Pten loss accelerates high-grade glioma development, we used a previously characterized RasB8 glioma-prone mouse strain, in which these specific genetic changes were focally introduced at 4 weeks of age. We show that both postnatal EGFRvIII expression and Pten inactivation in RasB8 mice potentiate high-grade glioma development. Moreover, we observe a concordant loss of Pten and EGFR overexpression in nearly all high-grade gliomas induced by either EGFRvIII introduction or Pten inactivation. This novel preclinical model of high-grade glioma will be useful in evaluating brain tumor therapies targeted to the pathways specifically dysregulated by EGFR expression or Pten loss.

Original languageEnglish
Pages (from-to)7429-7437
Number of pages9
JournalCancer Research
Volume66
Issue number15
DOIs
StatePublished - Aug 1 2006
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Glioma
Transgenic Mice
Brain Neoplasms
Mutation
epidermal growth factor receptor VIII
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High-grade glioma formation results from postnatal Pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. / Wei, Qingxia; Clarke, Laura; Scheidenhelm, Danielle K.; Qian, Baoping; Tong, Amanda; Sabha, Nesrin; Karim, Zia; Bock, Nicholas A.; Reti, Robert; Swoboda, Rolf; Purev, Enkhtsetseg; Lavoie, Jean Francois; Bajenaru, M. Livia; Shannon, Patrick; Herlyn, Dorothee; Kaplan, David; Henkelman, R. Mark; Gutmann, David H.; Guha, Abhijit.

In: Cancer Research, Vol. 66, No. 15, 01.08.2006, p. 7429-7437.

Research output: Contribution to journalArticle

Wei, Q, Clarke, L, Scheidenhelm, DK, Qian, B, Tong, A, Sabha, N, Karim, Z, Bock, NA, Reti, R, Swoboda, R, Purev, E, Lavoie, JF, Bajenaru, ML, Shannon, P, Herlyn, D, Kaplan, D, Henkelman, RM, Gutmann, DH & Guha, A 2006, 'High-grade glioma formation results from postnatal Pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model', Cancer Research, vol. 66, no. 15, pp. 7429-7437. https://doi.org/10.1158/0008-5472.CAN-06-0712
Wei, Qingxia ; Clarke, Laura ; Scheidenhelm, Danielle K. ; Qian, Baoping ; Tong, Amanda ; Sabha, Nesrin ; Karim, Zia ; Bock, Nicholas A. ; Reti, Robert ; Swoboda, Rolf ; Purev, Enkhtsetseg ; Lavoie, Jean Francois ; Bajenaru, M. Livia ; Shannon, Patrick ; Herlyn, Dorothee ; Kaplan, David ; Henkelman, R. Mark ; Gutmann, David H. ; Guha, Abhijit. / High-grade glioma formation results from postnatal Pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. In: Cancer Research. 2006 ; Vol. 66, No. 15. pp. 7429-7437.
@article{63177e29850a4a74b45b452695cd1838,
title = "High-grade glioma formation results from postnatal Pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model",
abstract = "High-grade gliomas are devastating brain tumors associated with a mean survival of <50 weeks. Two of the most common genetic changes observed in these tumors are overexpression/mutation of the epidermal growth factor receptor (EGFR) vIII and loss of PTEN/MMAC1 expression. To determine whether somatically acquired EGFRvIII expression or Pten loss accelerates high-grade glioma development, we used a previously characterized RasB8 glioma-prone mouse strain, in which these specific genetic changes were focally introduced at 4 weeks of age. We show that both postnatal EGFRvIII expression and Pten inactivation in RasB8 mice potentiate high-grade glioma development. Moreover, we observe a concordant loss of Pten and EGFR overexpression in nearly all high-grade gliomas induced by either EGFRvIII introduction or Pten inactivation. This novel preclinical model of high-grade glioma will be useful in evaluating brain tumor therapies targeted to the pathways specifically dysregulated by EGFR expression or Pten loss.",
author = "Qingxia Wei and Laura Clarke and Scheidenhelm, {Danielle K.} and Baoping Qian and Amanda Tong and Nesrin Sabha and Zia Karim and Bock, {Nicholas A.} and Robert Reti and Rolf Swoboda and Enkhtsetseg Purev and Lavoie, {Jean Francois} and Bajenaru, {M. Livia} and Patrick Shannon and Dorothee Herlyn and David Kaplan and Henkelman, {R. Mark} and Gutmann, {David H.} and Abhijit Guha",
year = "2006",
month = "8",
day = "1",
doi = "10.1158/0008-5472.CAN-06-0712",
language = "English",
volume = "66",
pages = "7429--7437",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - High-grade glioma formation results from postnatal Pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model

AU - Wei, Qingxia

AU - Clarke, Laura

AU - Scheidenhelm, Danielle K.

AU - Qian, Baoping

AU - Tong, Amanda

AU - Sabha, Nesrin

AU - Karim, Zia

AU - Bock, Nicholas A.

AU - Reti, Robert

AU - Swoboda, Rolf

AU - Purev, Enkhtsetseg

AU - Lavoie, Jean Francois

AU - Bajenaru, M. Livia

AU - Shannon, Patrick

AU - Herlyn, Dorothee

AU - Kaplan, David

AU - Henkelman, R. Mark

AU - Gutmann, David H.

AU - Guha, Abhijit

PY - 2006/8/1

Y1 - 2006/8/1

N2 - High-grade gliomas are devastating brain tumors associated with a mean survival of <50 weeks. Two of the most common genetic changes observed in these tumors are overexpression/mutation of the epidermal growth factor receptor (EGFR) vIII and loss of PTEN/MMAC1 expression. To determine whether somatically acquired EGFRvIII expression or Pten loss accelerates high-grade glioma development, we used a previously characterized RasB8 glioma-prone mouse strain, in which these specific genetic changes were focally introduced at 4 weeks of age. We show that both postnatal EGFRvIII expression and Pten inactivation in RasB8 mice potentiate high-grade glioma development. Moreover, we observe a concordant loss of Pten and EGFR overexpression in nearly all high-grade gliomas induced by either EGFRvIII introduction or Pten inactivation. This novel preclinical model of high-grade glioma will be useful in evaluating brain tumor therapies targeted to the pathways specifically dysregulated by EGFR expression or Pten loss.

AB - High-grade gliomas are devastating brain tumors associated with a mean survival of <50 weeks. Two of the most common genetic changes observed in these tumors are overexpression/mutation of the epidermal growth factor receptor (EGFR) vIII and loss of PTEN/MMAC1 expression. To determine whether somatically acquired EGFRvIII expression or Pten loss accelerates high-grade glioma development, we used a previously characterized RasB8 glioma-prone mouse strain, in which these specific genetic changes were focally introduced at 4 weeks of age. We show that both postnatal EGFRvIII expression and Pten inactivation in RasB8 mice potentiate high-grade glioma development. Moreover, we observe a concordant loss of Pten and EGFR overexpression in nearly all high-grade gliomas induced by either EGFRvIII introduction or Pten inactivation. This novel preclinical model of high-grade glioma will be useful in evaluating brain tumor therapies targeted to the pathways specifically dysregulated by EGFR expression or Pten loss.

UR - http://www.scopus.com/inward/record.url?scp=33747885901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747885901&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-0712

DO - 10.1158/0008-5472.CAN-06-0712

M3 - Article

VL - 66

SP - 7429

EP - 7437

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 15

ER -